Helix BioPharma awarded U. S. Patent for DOS47 adjunct chemotherapy applications
18 Sep 2007 - Helix BioPharma Corp announced the issuance of its second DOS47 patent (U. S. procure No. 7,264,800) from the United States procure & Trademark Office describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications.
"This procure offers a significant extension to Helix's DOS47 intellectual property lay opening up the possibility for expanded commercial opportunities," said Dr. Donald H. Segal. President and CEO of Helix. "We believe there is significant market potential to combine DOS47-based therapeutics with certain chemotherapeutic drugs in so-called adjunct regimens because DOS47 therapy is designed to act tumor acidity. Tumor acidity is a property that otherwise makes it difficult for weakly basic chemotherapeutics to come in cancer cells and answer effectively." With the granting of this second DOS47 patent. Helix now has procure protection covering the use of targeted DOS47-based therapeutics alone and in certain combined chemotherapy applications. Moving send the Company intends to act the development of DOS47 therapies for both applications with a believe to maximizing its DOS47 commercialization potential. At present. Helix is focused on the development of its first DOS47-based cancer therapeutic ("L-DOS47") which specifically targets lung adenocarcinoma. Helix has previously presented scientific findings which demonstrated the ability of L-DOS47 to destroy lung cancer cells alone and synergistically with selected chemotherapeutic compounds. Helix continues to go its manufacturing and preclinical development programs with a believe to arrange I human clinical testing. With this newly issued patent the Company is well-positioned to potentially broaden its late re-create clinical development program to consider both monotherapy and combined chemotherapy applications for L-DOS47.
&write; 2001-2007 Chemie. DE Information Service GmbH
a Life Science Network Division
Forex Groups - Tips on Trading
Related article:
http://www.bionity.com/news/e/69797/?WT.mc_id=ca0068
comments | Add comment | Report as Spam
|